A Phase 3 interventional study of guadecitabine and Treatment Choice (TC) in Acute Myeloid Leukemia, sponsored by Astex Pharmaceuticals, Inc.. Completed at 95 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. — 4 open to participants now, 6 under way, 2 of them phase 3. Leukemia, Myeloid, Acute · Otsuka Holdings Co., Ltd..
Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 8th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Canada, Czechia and 7 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Austria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 6 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 42 across the 20 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astex Pharmaceuticals, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
3 of the studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04953910Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | 2026-12 |
| NCT04953897Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone:
This Phase 3, randomized, open-label, parallel-group multicenter study of the efficacy and safety of guadecitabine in adults with previously treated acute myeloid leukemia (AML) will be conducted in approximately 20 countries. There will be a 14-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last approximately 2 years. Duration of individual participant participation will vary, and participants may continue to receive treatment for as long as they continue to benefit.
Approximately 404 participants from approximately 100 study centers will be randomly assigned to either guadecitabine or treatment choice (TC) in a 1:1 ratio (approximately 202 participants per group). TC is as follows:
Guadecitabine will be given subcutaneous (SC) at a dose of 60 microgram per meter square (mg/m\^2) in 28-day cycles. In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. Cycle 2 will be either the 5-day regimen (Days 1-5) or 10-day regimen (Days 1-5 and 8-12) based on assessment of disease response and hematologic recovery at the end of Cycle 1. In subsequent cycles, guadecitabine treatment will be for 5 days only (Days 1-5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Guadecitabine will be given SC at a dose of 60 mg/m\^2 in 28-day cycles (delayed as necessary to allow blood count recovery).
Drug: guadecitabine
1. High intensity 2. Low intensity 3. Best supportive care (BSC).
Drug: Treatment Choice (TC)
In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
Also known as: SGI-110
* High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida). * Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine. * Best Supportive Care (BSC).
Overall Survival
Overall survival is defined as number of days from day of randomization to date of death, regardless of cause.
Time frame: From the date of randomization until the date of death, or approximately 34 months
Event-Free Survival
Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant \[HCT\]), start of alternative anti-leukemia therapy (except HCT), or death.
Time frame: From the date of randomization until the date of death, or approximately 38 months
Long-Term Survival
Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate.
Time frame: Up to approximately 38 months
Number of Days Alive and Out of the Hospital (NDAOH)
Number of days participants alive and out of hospital during first 6 months of the study.
Time frame: 6 months
Transfusion Independence Rate
Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis.
Time frame: Baseline up to approximately 38 months
Complete Response Rate
The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.
Time frame: Baseline to end of treatment, or approximately 38 months
Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate
The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.
Time frame: Baseline to end of treatment, or approximately 38 months
Composite Complete Response Rate
Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC ≥1000/μL, platelets ≥100,000/μL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC ≥1000/μL, Platelets \<100,000/μL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC \<1000/μL, no leukemic blasts and bone marrow should contain less than 5% blast cells.
Time frame: Baseline to end of treatment, or approximately 38 months
Hematopoietic Cell Transplant (HCT) Rate
Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis.
Time frame: Baseline to long term follow-up or approximately 38 months
Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)
The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events): 1. relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or ≥5% leukemic blasts in BM, or clinical progression determined by the investigator), 2. start of alternative therapy (except HCT) or 3. death.
Time frame: Baseline to end of treatment, or approximately 38 months
Change From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores
Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England. The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).
Time frame: Baseline to 6 months
Change in EQ-5D-5L Visual Analogue Scale (VAS) Score
VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'.
Time frame: Baseline to 6 months
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.
Time frame: From first dose until 30 days after the last dose of study drug, or approximately 38 months
All-Cause Mortality
All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment.
Time frame: From the first dose until 60 days after the first dose of study drug
A total of 358 participants were assessed for study inclusion. Of these 56 failed screening assessments. A total of 302 participants were randomized (148 guadecitabine, 154 treatment choice \[TC\]). Of the randomized participants, 10 did not receive study drug (3 guadecitabine, 7 TC).
| Milestone | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Started | 148 | 154 |
| Safety analysis set | 145 | 147 |
| Completed | 28 | 20 |
| Not completed | 120 | 134 |
| Withdrew: Death | 117 | 127 |
| Withdrew: Withdrawal by subject | 3 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 |
Overall survival is defined as number of days from day of randomization to date of death, regardless of cause.
| days | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Overall Survival | 191.0 (141.0 to 253.0) | 163.0 (131.0 to 213.0) |
Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant \[HCT\]), start of alternative anti-leukemia therapy (except HCT), or death.
| days | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Event-Free Survival | 90.0 (73.0 to 105.0) | 71.5 (53.0 to 78.0) |
Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate.
| proportion | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| 12-month survival rate | 0.32 (0.25 to 0.40) | 0.26 (0.20 to 0.34) |
| 24-month survival rate | 0.19 (0.12 to 0.26) | 0.10 (0.05 to 0.17) |
Number of days participants alive and out of hospital during first 6 months of the study.
| days | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Number of Days Alive and Out of the Hospital (NDAOH) | 73.2 (53.2 to 93.2) | 73.9 (53.8 to 94.1) |
Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Overall transfusion independence | 20.3 | 13.0 |
| Platelet transfusion independence | 23.6 | 21.4 |
| RBC transfusion independence | 21.6 | 14.3 |
The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Complete Response Rate | 12.8 | 7.1 |
The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate | 16.9 | 7.8 |
Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC ≥1000/μL, platelets ≥100,000/μL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC ≥1000/μL, Platelets \<100,000/μL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC \<1000/μL, no leukemic blasts and bone marrow should contain less than 5% blast cells.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Composite Complete Response Rate | 27.0 | 14.3 |
Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Hematopoietic Cell Transplant (HCT) Rate | 17.6 | 16.2 |
The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events): 1. relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or ≥5% leukemic blasts in BM, or clinical progression determined by the investigator), 2. start of alternative therapy (except HCT) or 3. death.
| days | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh) | 124 (73.0 to 315.0) | 63 (8.0 to 71.0) |
Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England. The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).
| score on a scale | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Cycle 2 Day 1 | -0.027 (-0.061 to 0.007) | -0.034 (-0.068 to 0.001) |
| Cycle 3 Day 1 | -0.026 (-0.063 to 0.011) | -0.028 (-0.066 to 0.010) |
| Cycle 4 Day 1 | -0.008 (-0.050 to 0.034) | -0.061 (-0.108 to -0.015) |
| Cycle 5 Day 1 | -0.022 (-0.072 to 0.027) | -0.072 (-0.126 to -0.019) |
| Cycle 6 Day 1 | -0.027 (-0.071 to 0.017) | -0.070 (-0.188 to -0.022) |
| Cycle 7 Day 1 | -0.020 (-0.071 to 0.030) | -0.022 (-0.076 to 0.033) |
VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'.
| score on a scale | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Cycle 2 Day 1 | -2.80 (-6.26 to 0.65) | -1.86 (-5.40 to 1.67) |
| Cycle 3 Day 1 | -0.61 (-4.08 to 2.87) | -1.47 (-5.02 to 2.08) |
| Cycle 4 Day 1 | 1.13 (-2.24 to 4.51) | -2.37 (-6.04 to 1.29) |
| Cycle 5 Day 1 | 1.28 (-2.88 to 5.44) | -2.30 (-6.83 to 2.22) |
| Cycle 6 Day 1 | 0.67 (-3.51 to 4.85) | -1.42 (-6.04 to 3.21) |
| Cycle 7 Day 1 | -0.44 (-5.66 to 4.78) | -0.77 (-6.46 to 4.93) |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 96.6 | 97.3 |
All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment.
| percentage of participants | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Within 30 days | 11.7 | 9.5 |
| Within 60 days | 24.8 | 20.4 |
Collected over From first dose until 30 days after the last dose of study drug, or approximately 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Guadecitabine | 117/148 (79.1%) | 113/145 (77.9%) | 138/145 (95.2%) |
| Treatment Choice (TC) | 129/154 (83.8%) | 91/147 (61.9%) | 137/147 (93.2%) |
| Event | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 41/145 | 33/147 |
| PneumoniaInfections and infestations | 27/145 | 25/147 |
| SepsisInfections and infestations | 15/145 | 16/147 |
| Septic shockInfections and infestations | 7/145 | 5/147 |
| PyrexiaGeneral disorders | 5/145 | 6/147 |
| BacteraemiaInfections and infestations | 4/145 | 5/147 |
| Cardiac arrestCardiac disorders | 4/145 | 0/147 |
| Febrile bone marrow aplasiaBlood and lymphatic system disorders | 4/145 | 3/147 |
| Bronchopulmonary aspergillosisInfections and infestations | 4/145 | 0/147 |
| CellulitisInfections and infestations | 4/145 | 2/147 |
| Event | Guadecitabine | Treatment Choice (TC) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 47/145 | 28/147 |
| ThrombocytopeniaBlood and lymphatic system disorders | 43/145 | 46/147 |
| NauseaGastrointestinal disorders | 42/145 | 38/147 |
| AnaemiaBlood and lymphatic system disorders | 37/145 | 41/147 |
| HypokalaemiaMetabolism and nutrition disorders | 29/145 | 38/147 |
| DiarrhoeaGastrointestinal disorders | 36/145 | 32/147 |
| PyrexiaGeneral disorders | 33/145 | 36/147 |
| ConstipationGastrointestinal disorders | 33/145 | 33/147 |
| HeadacheNervous system disorders | 30/145 | 20/147 |
| Injection site reactionGeneral disorders | 29/145 | 12/147 |
| Age, Continuous(years) | Guadecitabine | Treatment Choice (TC) | Total |
|---|---|---|---|
| Mean | 61.8 ± 12.2 | 59.8 ± 13.1 | 60.8 ± 12.7 |
| Sex: Female, Male(Participants) | Guadecitabine | Treatment Choice (TC) | Total |
|---|---|---|---|
| Female | 62 | 76 | 138 |
| Male | 86 | 78 | 164 |
| Ethnicity (NIH/OMB)(Participants) | Guadecitabine | Treatment Choice (TC) | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 16 | 34 |
| Not Hispanic or Latino | 113 | 114 | 227 |
| Unknown or Not Reported | 17 | 24 | 41 |
| Race/Ethnicity, Customized(Participants) | Guadecitabine | Treatment Choice (TC) | Total |
|---|---|---|---|
| White | 95 | 90 | 185 |
| Black or African American | 3 | 6 | 9 |
| Asian | 30 | 34 | 64 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Not Reported | 19 | 24 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Jan 2020, 34 months.
Results were first posted in May 2023, 3 years 4 months after primary completion. A results delay was requested in Jan 2021.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 34 months is below that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guadecitabine